Welltower Valuation

Is WELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: WELL ($137.4) is trading above our estimate of fair value ($123.84)

Significantly Below Fair Value: WELL is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for WELL?

Key metric: As WELL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for WELL. This is calculated by dividing WELL's market cap by their current earnings.
What is WELL's PE Ratio?
PE Ratio93.4x
EarningsUS$915.62m
Market CapUS$86.04b

Price to Earnings Ratio vs Peers

How does WELL's PE Ratio compare to its peers?

The above table shows the PE ratio for WELL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.5x
ARE Alexandria Real Estate Equities
64.5x20.6%US$18.3b
DOC Healthpeak Properties
48.5x-22.3%US$15.3b
OHI Omega Healthcare Investors
30.9x9.6%US$11.1b
CTRE CareTrust REIT
58.1x45.5%US$5.8b
WELL Welltower
93.4x15.0%US$86.0b

Price-To-Earnings vs Peers: WELL is expensive based on its Price-To-Earnings Ratio (93.4x) compared to the peer average (53.2x).


Price to Earnings Ratio vs Industry

How does WELL's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
WELL 93.4xIndustry Avg. 26.5xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: WELL is expensive based on its Price-To-Earnings Ratio (93.4x) compared to the Global Health Care REITs industry average (26.5x).


Price to Earnings Ratio vs Fair Ratio

What is WELL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WELL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio93.4x
Fair PE Ratio44.7x

Price-To-Earnings vs Fair Ratio: WELL is expensive based on its Price-To-Earnings Ratio (93.4x) compared to the estimated Fair Price-To-Earnings Ratio (44.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst WELL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$137.40
US$136.37
-0.8%
12.7%US$190.00US$114.00n/a19
Nov ’25US$133.27
US$131.95
-1.0%
13.5%US$190.00US$111.00n/a19
Oct ’25US$127.58
US$124.47
-2.4%
9.0%US$148.00US$107.00n/a19
Sep ’25US$120.68
US$120.74
+0.05%
7.4%US$137.00US$106.00n/a19
Aug ’25US$112.39
US$110.97
-1.3%
6.8%US$129.00US$100.00n/a19
Jul ’25US$104.00
US$107.89
+3.7%
8.0%US$129.00US$95.00n/a19
Jun ’25US$103.67
US$106.32
+2.6%
8.0%US$129.00US$92.00n/a19
May ’25US$94.36
US$103.95
+10.2%
8.2%US$129.00US$92.00n/a19
Apr ’25US$91.99
US$104.06
+13.1%
8.6%US$129.00US$92.00n/a17
Mar ’25US$92.72
US$101.05
+9.0%
10.0%US$129.00US$78.00n/a19
Feb ’25US$88.23
US$97.00
+9.9%
7.5%US$115.00US$78.00n/a19
Jan ’25US$90.17
US$94.78
+5.1%
7.3%US$111.00US$78.00n/a18
Dec ’24US$89.46
US$93.28
+4.3%
7.9%US$111.00US$78.00n/a18
Nov ’24US$85.43
US$91.06
+6.6%
8.4%US$111.00US$78.00US$133.2718
Oct ’24US$81.92
US$91.28
+11.4%
8.5%US$111.00US$78.00US$127.5818
Sep ’24US$82.64
US$89.82
+8.7%
9.6%US$111.00US$74.00US$120.6817
Aug ’24US$84.60
US$85.94
+1.6%
7.8%US$98.00US$73.00US$112.3917
Jul ’24US$80.89
US$86.24
+6.6%
10.7%US$111.00US$70.00US$104.0017
Jun ’24US$74.61
US$85.21
+14.2%
10.3%US$111.00US$70.00US$103.6719
May ’24US$78.26
US$83.16
+6.3%
10.8%US$111.00US$70.00US$94.3619
Apr ’24US$71.69
US$82.16
+14.6%
11.5%US$111.00US$70.00US$91.9919
Mar ’24US$73.09
US$82.55
+12.9%
11.3%US$111.00US$70.00US$92.7220
Feb ’24US$74.88
US$79.62
+6.3%
12.9%US$111.00US$64.00US$88.2321
Jan ’24US$65.55
US$78.81
+20.2%
13.3%US$111.00US$61.00US$90.1721
Dec ’23US$70.99
US$79.24
+11.6%
13.5%US$111.00US$61.00US$89.4621
Nov ’23US$60.10
US$79.76
+32.7%
15.2%US$111.00US$61.00US$85.4321

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies